Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.38
-11.99 (-4.57%)
AAPL  348.22
+4.23 (1.23%)
AMD  507.93
-44.79 (-8.10%)
BAC  51.08
+0.30 (0.59%)
GOOG  320.76
-10.19 (-3.08%)
META  648.85
-48.67 (-6.98%)
MSFT  521.08
-11.87 (-2.23%)
NVDA  212.21
-9.76 (-4.40%)
ORCL  125.54
-3.59 (-2.78%)
TSLA  374.58
-11.89 (-3.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.